Last reviewed · How we verify
IV pantoprazole
IV pantoprazole inhibits gastric acid secretion by blocking the proton pump (H+/K+-ATPase) in parietal cells of the stomach.
IV pantoprazole inhibits gastric acid secretion by blocking the proton pump (H+/K+-ATPase) in parietal cells of the stomach. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Stress ulcer prophylaxis in critically ill patients.
At a glance
| Generic name | IV pantoprazole |
|---|---|
| Sponsor | Pfizer |
| Drug class | Proton pump inhibitor (PPI) |
| Target | H+/K+-ATPase (proton pump) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Pantoprazole is a proton pump inhibitor (PPI) that irreversibly binds to and inactivates the H+/K+-ATPase enzyme on the secretory surface of gastric parietal cells. This blocks the final step of gastric acid production, reducing intragastric pH and providing rapid acid suppression. The IV formulation allows for direct systemic delivery in patients unable to take oral medication.
Approved indications
- Gastroesophageal reflux disease (GERD)
- Peptic ulcer disease
- Stress ulcer prophylaxis in critically ill patients
- Zollinger-Ellison syndrome
Common side effects
- Headache
- Diarrhea
- Nausea
- Abdominal pain
- Injection site reactions
- Hypomagnesemia
Key clinical trials
- Prevention of Post-Cardiac Surgery Acute Kidney Injury by Proton Pump Inhibitor (PHASE2)
- High Dose Oral Omeprazole in High Risk UGIB (NA)
- Benson Relaxation Technique Effectiveness on Pain and Quality of Life Post Reconstructive Mammoplasty (NA)
- PREA, PK And Safety PASS Study Of IV Pantoprazole In Pediatric Subjects (PHASE4)
- Efficacy of Vonoprazan Versus Intravenous Proton Pump Inhibitors for Prevention of Rebleeding in High Risk Peptic Ulcers Bleeding After Successful Endoscopic Hemostasis (EARLY_PHASE1)
- Role of Octreotide in Non Variceal Bleeding (PHASE2, PHASE3)
- Pediatric Intensive Care Ulcer Prophylaxis Pilot Trial (PHASE3)
- Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IV pantoprazole CI brief — competitive landscape report
- IV pantoprazole updates RSS · CI watch RSS
- Pfizer portfolio CI